Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Depression and cognitive impairment in the elderly: a multicentre study.

European psychiatry : the journal of the Association of European Psychiatrists·2009
Same author

Biological study of alcohol dependence syndrome with reference to ethnic difference: report of a WHO Collaborative Study.

The Japanese journal of psychiatry and neurology·1990
Same author

[Treatment of drug-resistant depression by intravenous administration of antidepressants].

Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952)·1990
Same author

[Diagnosis and therapy of depression in the elderly].

Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis·1987
Same author

Dose relationships of morning bright white light in seasonal affective disorders (SAD).

Experientia·1987
Same author

Light treatment of seasonal affective disorder in Switzerland.

Acta psychiatrica Scandinavica·1986

Related Experiment Video

Updated: Jul 11, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

New psychotropic drug developments in German speaking countries.

P Kielholz1

  • 1Psychiatrische Universitätsklinik, Wilhelm-Klein-Str. 27, CH-4052 Basel, Switzerland.

Diseases of the Nervous System
|July 1, 1974
PubMed
Summary

Europe sees stagnation in new psychotropic drug development. Maprotiline, a novel antidepressant, offers mood elevation and anxiolytic effects with minimal side effects, benefiting cardiac patients and the elderly.

Area of Science:

  • Psychopharmacology
  • Neuroscience
  • Drug Development

Background:

  • Stagnation in novel psychotropic drug development in Europe since lithium and long-term neuroleptics.
  • Limited introduction of new antidepressants, neuroleptics, and tranquilizers in recent years.
  • Focus on drugs with specific activity spectra and indication ranges.

Purpose of the Study:

  • To review recent advancements in psychotropic drug development in Europe.
  • To highlight the characteristics of newly developed antidepressants, neuroleptics, and tranquilizers.
  • To present chemical structures, indications, and side effects of these new drugs.

Main Methods:

  • Review of recently developed psychotropic medications.
  • Analysis of pharmacological profiles, including efficacy, side effects, and indications.

More Related Videos

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Related Experiment Videos

Last Updated: Jul 11, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

  • Presentation of chemical structures and their relation to drug activity.

    • Main Results:

    • Introduction of maprotiline, a dibenzo-bicyclo-octadiene antidepressant with mood-elevating, anxiolytic, and minimal cardiovascular effects.
    • Maprotiline shows prompt onset of action and is suitable for patients with heart conditions and the elderly.
    • Development trends include long-acting and rapidly effective neuroleptics, and anxiolytics with mild sedative effects.

    Conclusions:

    • Maprotiline represents a significant advancement in antidepressant therapy, particularly for anxious and retarded depressive states.
    • The development of neuroleptics and tranquilizers is trending towards improved efficacy, safety, and patient-specific applications.
    • Further research into novel psychotropic agents is crucial to address unmet clinical needs.